| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 361.0 | 265.2 |
| Profit before tax | -124.0 | -92.6 |
| Net income | -124.4 | -92.7 |
| EPS (diluted, $ a share) | $-0.93 | $-0.74 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +36.1% |
|---|---|
| Operating margin | -36.8% |
10-Q filed with the SEC, NASDAQ: GH. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Guardant Health, Inc.: key numbers
- Share price
- $143.28Close, Nov 17
- Market cap
- $19.4B
- Shares outstanding
- 135.29MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-Medical LaboratoriesSIC 8071
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Guardant Health, Inc.
All →Guardant Health $550M Debt Financing with U.S. Bank Trust Company, National Association
Guardant Health completed a private offering of $550 million in 0% Convertible Senior Notes due 2032, which included the full exercise of the initial purchasers' option for an additional $50 million. The notes feature an initial conversion price of approximately $208.95 per share, representing a 35% premium over the November 11, 2026 closing price. Proceeds will be used to repurchase a portion of the company's existing 2027 convertible notes, fund capped call transactions, and for general corporate purposes.
- Value
- $550M
- Counterparty
- U.S. Bank Trust Company, National Association
- Term
- through May 2032
Guardant Health Financial Results
Guardant Health reported Q3 2026 revenue of $361.0 million, a 36% increase year-over-year, driven by strong performance in its Oncology and Screening segments. The company raised its full-year 2026 revenue guidance to a range of $1.36 billion to $1.37 billion and highlighted the FDA approval of Guardant360 CDx as a companion diagnostic for breast cancer.
- Term
- Q3 2026
“Revenue grew 36% year over year as we continued to execute across Oncology, Screening, and Biopharma. Oncology volume grew 58% with broad contributions across our portfolio. The FDA approval of Guardant360 CDx for longitudinal ESR1 testing is a major advance for breast cancer patients, ushering in a new paradigm of cancer treatment. It reinforces the role of Guardant360 in enabling earlier therapy decisions and strengthens our leadership across the cancer care continuum.”
Helmy Eltoukhy, co-founder and co-CEO
“Shield continued to build momentum in the third quarter, with volume more than tripling year over year to 83,000 tests. Commercial coverage continues to expand, with recent policy updates extending Shield coverage to approximately 100 million lives. With our lower COGS, higher-throughput workflow now fully implemented, we have a strong operational foundation to meet future Shield demand. Together, these advances expand access to Shield and move us closer to making blood-based cancer screening a routine part of preventive care.”
AmirAli Talasaz, co-founder and co-CEO
Guardant Health Executive Compensation
Guardant Health appointed Kevin R. Sayer, former CEO of Dexcom, to its Board of Directors and named Robert A. Parks as Chief Accounting Officer. Mr. Sayer will receive an annual cash retainer of $60,000 and an initial restricted stock unit award valued at $500,000 vesting over three years.
- Counterparty
- Kevin R. Sayer
- Term
- 3 years
Guardant Health Stock Plan Amendment
Guardant Health granted performance-based restricted stock units (PSUs) to Co-CEOs Helmy Eltoukhy and AmirAli Talasaz under the 2018 Incentive Award Plan. Each executive received 465,413 PSUs at target, with vesting 100% tied to the company's total shareholder return (TSR) relative to the S&P 500 Index over three-year and five-year periods. The awards include a cap at 100% of target if absolute TSR is negative and require additional post-vesting holding periods.
- Term
- 5 years
Guardant Health Insider Musa Tariq Sells $19.2K of Stock
Musa Tariq sold 116 shares of Guardant Health, Inc. at $165.88 a share, worth $19.2K in total on Oct 16, 2026. Shares held after the trade: 11,583 (-1.0%).
- Value
- $19.2K
- Shares
- 116
- Price
- $165.88
- Holding change
- -1.0%
- Trade date
- Oct 16, 2026
Guardant Health Insider Alex M. Azar II Sells $11K of Stock
Alex M. Azar II sold 69 shares of Guardant Health, Inc. at $159.89 a share, worth $11K in total on Oct 14, 2026. Shares held after the trade: 893 (-7.2%).
- Value
- $11K
- Shares
- 69
- Price
- $159.89
- Holding change
- -7.2%
- Trade date
- Oct 14, 2026